Pancreatitis News and Research

RSS

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

New screening marker can detect pancreatic cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a protein that shows distinct changes in structure between pancreatic cancer, non-cancerous diseases and normal blood serum. The protein also changes from early stage pancreatic cancer to advanced disease.

28 Apr 2011

Scientists develop new low cost test for acute pancreatitis

A new low cost test for acute pancreatitis that gets results much faster than existing tests has been developed by scientists at The University of Texas at Austin.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin Pharmaceuticals, Inc. today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.

16 Apr 2011

Eli Lilly receives FDA complete response letter for liprotamase NDA

Eli Lilly and Company has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for liprotamase, a non-porcine pancreatic enzyme replacement therapy, under investigation for the treatment of exocrine pancreatic insufficiency.

16 Apr 2011

Consumer group calls for ban on weight loss drugs Alli and Xenical

According to the consumer watchdog Public Citizen, the weight loss drugs Alli and Xenical should be removed from the market because of the growing risk of side effects that include liver damage, pancreatitis and kidney stones.

15 Apr 2011

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

New insight into acute pancreatitis

Timing is everything. That's especially true when it comes to the activation of enzymes created by the pancreas to break down food. When the timing is right, those enzymes are activated only when they reach the gut, where they get to work releasing and distributing nutrients that we need to survive.

8 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Food safety lawyer calls on Palmyra to pay medical expenses incurred by E. coli outbreak victims

Food safety lawyer Fred Pritzker is calling on Palmyra Bologna Company, Inc., maker of Seltzer's Lebanon bologna products, to pay medical expenses and other costs incurred by victims of a multistate E. coli O157:H7 outbreak in New Jersey, North Carolina and Pennsylvania.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Cardiff study discovers protein that protects pancreatic cells against alcohol effects

A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.

23 Mar 2011

Heavy alcohol consumption linked to increased risk of death from pancreatic cancer

Heavy alcohol consumption, specifically three or more glasses of liquor a day, is associated with an increased risk of death from pancreatic cancer, according to a report in the March 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Mar 2011

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Repligen Corporation reported today positive top-line results from a Phase 3 study to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with pancreatic disease using endoscopy (ERCP) as a diagnostic reference.

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

New study: Alcohol-related chronic pancreatitis is lower than other causes

The relative rate of alcohol-related chronic pancreatitis is lower when compared to other causes, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

14 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Pancreatitis News and Research

Further Reading

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

New screening marker can detect pancreatic cancer

Scientists develop new low cost test for acute pancreatitis

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Eli Lilly receives FDA complete response letter for liprotamase NDA

Consumer group calls for ban on weight loss drugs Alli and Xenical

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

New insight into acute pancreatitis

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Food safety lawyer calls on Palmyra to pay medical expenses incurred by E. coli outbreak victims

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Cardiff study discovers protein that protects pancreatic cells against alcohol effects

Heavy alcohol consumption linked to increased risk of death from pancreatic cancer

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

New study: Alcohol-related chronic pancreatitis is lower than other causes

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News